Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04994795 · ClinicalTrials.gov registry record

Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer

A clinical trial of Non Small Cell Lung Cancer Metastatic, sponsored by Sophia Genetics SAS.

Active
Registry status
4,000
Enrollment target
20
Study locations

NCT04994795 is a study of Non Small Cell Lung Cancer Metastatic that is active but no longer recruiting, run by Sophia Genetics SAS. The registered enrollment target is 4,000 participants, above the 187-participant average among 16 other Non Small Cell Lung Cancer Metastatic trials with a reported enrollment target (2039% higher). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04994795, a study of Non Small Cell Lung Cancer Metastatic, is active but no longer recruiting, sponsored by Sophia Genetics SAS.

ACTIVE NOT RECRUITING
Registry status
4,000 participants
Enrollment target
20
Study locations

Study Summary

Predicting response to therapy and disease progression in stage IV NSCLC patients treated with pembrolizumab monotherapy, chemotherapy-pembrolizumab combination therapy or chemotherapy alone in the first-line setting.

Conditions Studied

Non Small Cell Lung Cancer Metastatic

Interventions

  • OTHER Predictive models (data collection)

Study Locations (20)

Other

  • DASA - Hospital Brasilia - Brasília
  • DASA - Hospital de Niteroi - Niterói
  • DASA - Hospital São Lucas - Rio de Janeiro
  • DASA - Hospital Nove De Julho - São Paulo
  • AC Camargo - São Paulo
  • Sunnybrook Health Sciences Centre Toronto - Toronto
  • Avicenne Hospital - Bobigny
  • CHU Bordeaux - Bordeaux
  • Ambroise Paré Hospital - Boulogne-Billancourt
  • Hospices Civils de Lyon - Lyon
  • CHU de Nantes - Nantes
  • La Pitié Salpêtrière - Paris
  • Tenon Hospital - Paris
  • Foch Hospital - Suresnes

Iowa

  • Holden Comprehensive Cancer Center at University of Iowa Health Care - Iowa City

Massachusetts

  • UMASS Memorial Health - Worcester

Minnesota

  • Mayo Clinic - Rochester

New York

  • Roswell Park Comprehensive Cancer Center - Buffalo

Utah

  • Huntsman Cancer Institute - Salt Lake City

Wisconsin

  • Carbone Comprehensive Cancer Center at University of Wisconsin - Madison

Trial Details

FieldValue
Enrollment Target 4,000 participants
Start Date 2021-08-21
Est. Completion 2025-02

Sponsor

Sophia Genetics SAS

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04994795

The ClinicalTrials.gov registry entry for NCT04994795 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 4,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 187-participant average among 16 other Non Small Cell Lung Cancer Metastatic trials with a reported enrollment target (2039% higher). The listed sponsor is Sophia Genetics SAS, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Non Small Cell Lung Cancer Metastatic appearing as the primary indexed condition, and to 1 intervention - of which Predictive models (data collection) is the first listed.

NCT04994795 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, Iowa, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04994795 about?

NCT04994795 is a clinical study titled "Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer". Predicting response to therapy and disease progression in stage IV NSCLC patients treated with pembrolizumab monotherapy, chemotherapy-pembrolizumab combination therapy or chemotherapy alone in the first-line setting.

What is the current status of trial NCT04994795?

This trial is currently active not recruiting. The enrollment target is 4,000 participants. The study started on 2021-08-21. Estimated completion is 2025-02.

What conditions does trial NCT04994795 study?

This clinical trial studies the following conditions: Non Small Cell Lung Cancer Metastatic.

What interventions are being tested in trial NCT04994795?

The interventions under investigation include: Predictive models (data collection) (OTHER).

Who is sponsoring clinical trial NCT04994795?

This trial is sponsored by Sophia Genetics SAS, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04994795 being conducted?

This trial has 20 study locations across Iowa, Massachusetts, Minnesota, New York, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non Small Cell Lung Cancer Metastatic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non Small Cell Lung Cancer Metastatic

All registered trials for this condition

Iowa

All trials with a study site in Iowa

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.